Haloperidol vs Conventional Therapy for Gastroparesis

• Status: Terminated
• Trial end date: 2016-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Randomized controlled trial comparing haloperidol combined with conventional therapy and conventional therapy alone in patients with symptomatic gastroparesis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center, Houston
• Treatments: Haloperidol; Haloperidol decanoate

Criteria

Inclusion Criteria:

• Previous diagnosis of GP including those without formal gastric emptying studies.

• Patients presenting with unresolving nausea, vomiting, and abdominal pain that is attributable to their GP.

Exclusion Criteria:

• History of QT prolongation or presence on a 12 leads electrocardiogram.

• Presence of concomitant acute abdominal pathology including but not limited to hepatobiliary disease, ischemia, and abdominal aneurysm.

• Prisoners

• Hypotension (systolic blood pressure below 90 mm Hg)

• Pregnant women

• Patients who are cognitively impaired and/or unable to consent for the study

• Age <18

• Allergy to haloperidol